Naveen Pemmaraju/mdanderson.org
May 23, 2025, 06:34
Naveen Pemmaraju: SMAC Mimetics as Potential Cancer Therapeutics in Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, posted on X:
“SMAC Mimetics/IAP antagonist in myeloid malignancies. British Journal of Haematology.”
Title: SMAC Mimetics as Potential Cancer Therapeutics in Myeloid Malignancies
Authors: Prajwal Boddu, Bing Z. Carter, Srdan Verstovsek, Naveen Pemmaraj
Read The Full Article at British Journal of Haematology.
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38